Marinus Pharmaceuticals reported $40.4M in Equity Capital and Reserves for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Equity Capital And Reserves Change
Acadia Pharmaceuticals ACAD:US $ 444.8M 96.1M
ALKERMES ALKS:US $ 1075.39M 37.19M
Amgen AMGN:US $ 916M 5784M
Aptinyx Inc APTX:US $ 77.48M 17.27M
Biogen BIIB:US $ 11242.3M 346.1M
Eisai 4523:JP Y 748822M 14034M
Enanta Pharmaceuticals ENTA:US $ 358.58M 25.8M
Esperion Therapeutics ESPR:US $ -249040000 52.1M
Gilead Sciences GILD:US $ 19927M 1142M
Intercept Pharmaceuticals ICPT:US $ -371.76M 187.8M
Intra Cellular Therapies ITCI:US $ 792.75M 374.86M
Marinus Pharmaceuticals MRNS:US $ 40.4M 13.08M
Minerva Neurosciences NERV:US $ -0.74M 8.71M
Neurocrine Biosciences NBIX:US $ 1391.1M 17.1M
Ptc Therapeutics PTCT:US $ -90.58M 92.02M
Regeneron Pharmaceuticals REGN:US $ 19914.7M 1145.9M
Sarepta Therapeutics SRPT:US $ 856.89M 71.12M
Supernus Pharmaceuticals SUPN:US $ 828.45M 12.6M
Vertex Pharmaceuticals VRTX:US $ 10907M 807M
YTE INCY:US $ 3863.07M 93.07M